Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 2/2014

01.04.2014 | Original Article

Variation of Papp-A Level in the First Trimester of Pregnancy and Its Clinical Outcome

verfasst von: Mithil Patil, T. M. Panchanadikar, Girija Wagh

Erschienen in: The Journal of Obstetrics and Gynecology of India | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Abnormalities in maternal serum marker levels and fetal measurements obtained during the first trimester screening can be a marker not only for certain chromosomal disorders and anomalies in the fetus but also for specific pregnancy complications. In particular, low maternal serum pregnancy-associated plasma protein-A (PAPP-A), at 11–13 weeks of gestation, is associated with stillbirth, infant death, intrauterine growth restriction, preterm birth, and pre-eclampsia in chromosomally normal fetuses, while a raised nuchal translucency is associated with specific structural abnormalities and genetic syndromes. We have studied the serum Papp-A level in 560 pregnant patients (11–13 weeks gestation) registered at Bharati Hospital and Research Centre, Pune. All patients undergoing testing were followed till the delivery and their neonatal outcome was also taken into consideration.

Aims and Objectives

Our aim is to study the pregnancy outcome in relation to the variations of Papp-A level in the first trimester of pregnancy.

Materials and Methods

Every patient visiting the antenatal OPD was counseled for testing of First Trimester Screening to assess fetal well-being. Patients who were registered for delivery at our hospital were taken into the trial. Blood samples were taken at 11–13 weeks of pregnancy and sent to the PerkinElmer lab for analysis. Results were expressed in Multiple of Median and patients having MOM value less than 0.5 were carefully observed till the delivery, and a thorough neonatal examination was done by a pediatrician.

Observations

524 patients were included in the trial out of which 452 patients were found to have a normal Papp-A level of >0.5 MOM. All these patients were followed further during the antenatal period where 18 patients developed preterm labor and few patients developed pregnancy-induced hypertension. The obstetric outcome of patients with a normal Papp-A level was fairly uneventful as compared to others with a low Papp-A level.

Conclusions

Though Papp-A level in the first trimester of pregnancy (11–13 weeks) is an important predictor of future obstetric outcome, it has poor positive predictive value. Patients having a Papp-A level less than 0.5 MOM have a high risk for preterm delivery, fetal growth restriction, and stillbirths along with increased incidence of hypertensive disorders of pregnancy. A low Papp-A level is a useful indicator of risk of preterm delivery and future chance of development of pregnancy-induced hypertension.
Literatur
1.
Zurück zum Zitat Proctor LK, Toal M, Keating S, et al. Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. Ultrasounds Obstet Gynecol. 2009;34(3):274–82.CrossRef Proctor LK, Toal M, Keating S, et al. Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. Ultrasounds Obstet Gynecol. 2009;34(3):274–82.CrossRef
2.
Zurück zum Zitat Gagnon A, Wilson RD, Audibert F, et al. Obstetrical complications associated with abnormal maternal serum marker analytes. J Obstet Gynaecol Can. 2008;30(10):918–49.PubMed Gagnon A, Wilson RD, Audibert F, et al. Obstetrical complications associated with abnormal maternal serum marker analytes. J Obstet Gynaecol Can. 2008;30(10):918–49.PubMed
3.
Zurück zum Zitat Jacob A, Canick JA, Messerlian GM et al (2010) Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening. Jacob A, Canick JA, Messerlian GM et al (2010) Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening.
4.
Zurück zum Zitat Krantz D, Goetzl L, Simpson JL. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004;191(4):1452.PubMedCrossRef Krantz D, Goetzl L, Simpson JL. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004;191(4):1452.PubMedCrossRef
5.
Zurück zum Zitat Spencer K, Cowans NJ, Chefetz I, et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;29(2):128–34.PubMedCrossRef Spencer K, Cowans NJ, Chefetz I, et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007;29(2):128–34.PubMedCrossRef
6.
Zurück zum Zitat Filippi E, Staughton J, Peregrine E, et al. Uterine artery Doppler and adverse pregnancy outcome in women with extreme levels of fetoplacental proteins used for down syndrome screening. Ultrasound Obstet Gynecol. 2011;37(5):520–7.PubMedCrossRef Filippi E, Staughton J, Peregrine E, et al. Uterine artery Doppler and adverse pregnancy outcome in women with extreme levels of fetoplacental proteins used for down syndrome screening. Ultrasound Obstet Gynecol. 2011;37(5):520–7.PubMedCrossRef
7.
Zurück zum Zitat Cnossen JS, Morris RK, Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008;178(6):701–11.PubMedCentralPubMedCrossRef Cnossen JS, Morris RK, Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008;178(6):701–11.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Handschuh K, et al. Low PAPP-A: what are the clinical implications? Placenta. 2006;27(Suppl A):S127–34.PubMedCrossRef Handschuh K, et al. Low PAPP-A: what are the clinical implications? Placenta. 2006;27(Suppl A):S127–34.PubMedCrossRef
9.
Zurück zum Zitat Bowman CJ, Streck RD, Chapin RE. Maternal-placental insulin-like growth factor (IGF) signaling and its importance to normal embryo-fetal development. Birth Defects Res B. 2010;17:10–8. Bowman CJ, Streck RD, Chapin RE. Maternal-placental insulin-like growth factor (IGF) signaling and its importance to normal embryo-fetal development. Birth Defects Res B. 2010;17:10–8.
11.
Zurück zum Zitat Ultrasound Obstet Gynecol 2006;28:637-43. Ultrasound Obstet Gynecol 2006;28:637-43.
12.
Zurück zum Zitat Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn. 2007;27(3):264–71.PubMedCrossRef Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn. 2007;27(3):264–71.PubMedCrossRef
13.
Zurück zum Zitat Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191(6):1446–51.PubMedCrossRef Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191(6):1446–51.PubMedCrossRef
Metadaten
Titel
Variation of Papp-A Level in the First Trimester of Pregnancy and Its Clinical Outcome
verfasst von
Mithil Patil
T. M. Panchanadikar
Girija Wagh
Publikationsdatum
01.04.2014
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe 2/2014
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-013-0481-4

Weitere Artikel der Ausgabe 2/2014

The Journal of Obstetrics and Gynecology of India 2/2014 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.